The definition of "non-metastatic hormone-sensitive prostate cancer" (nmHSPC) can be applied to patients with prostate cancer (PC) who are androgen-deprivation therapy-naïve and without evidence of metastatic disease. This definition includes heterogeneous situations; however, PC patients at high risk of metastatic spread - and who have not started a hormonal treatment - constitute a unique category with unmet clinical needs. This narrative review critically discusses the advances that characterize the rapidly evolving diagnostic and therapeutic scenario in the nmHSPC setting. We found that nmHSPC represents a grey zone in the context of PC. New clinical trials are trying to redefine the therapeutic algorithm of these patients, but escalating treatment seems not to be the right choice for the overall population. Biomarkers able to stratify patients - including molecular ones - are urgently needed, and biomarker-based clinical trials could clarify their prognostic and predictive role in the nmHSPC scenario.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.critrevonc.2024.104534 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Darolutamide in Combination with Radium-223 Exhibits Synergistic Antitumor Efficacy in LNCaP Prostate Cancer Models.
Int J Mol Sci
December 2024
Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany.
Despite treatment, prostate cancer commonly progresses into castration-resistant prostate cancer (CRPC), which remains largely incurable, requiring the development of new interventions. Darolutamide is an orally administered second-generation androgen receptor inhibitor indicated for patients with non-metastatic CRPC or metastatic hormone-sensitive prostate cancer. Here, we evaluated the effect of androgen receptor (AR) inhibition by darolutamide in combination with DNA double-strand-break-inducing targeted radium-223 alpha therapy in vitro and in an intratibial LNCaP xenograft model mimicking prostate cancer metastasized to bone.
View Article and Find Full Text PDFLow- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET-An International Multicenter Retrospective Study.
J Nucl Med
January 2025
Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
Article Synopsis
- The study compares the definitions of high-volume disease (HVD) and low-volume disease (LVD) in metastatic hormone-sensitive prostate cancer (mHSPC) patients using both conventional imaging (CI) and prostate-specific membrane antigen (PSMA) PET imaging, highlighting the need for more accurate definitions for treatment decisions.
- Researchers analyzed data from 67 mHSPC patients across five international sites who had both PSMA PET and CI scans within a specific timeframe, assessing how many were classified as HVD or LVD based on each imaging method.
- Results showed a significant discrepancy in classification: 25.4% of patients were identified as HVD using CI, while 40.3% were identified as HVD using
PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging.
JAMA Netw Open
January 2025
Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles.
Importance: The phase 3 randomized EMBARK trial evaluated enzalutamide with or without leuprolide in high-risk nonmetastatic hormone-sensitive prostate cancer. Eligibility relied on conventional imaging, which underdetects metastatic disease compared with prostate-specific membrane antigen-positron emission tomography (PSMA-PET).
Objective: To describe the staging information obtained by PSMA-PET/computed tomography (PSMA-PET/CT) in a patient cohort eligible for the EMBARK trial.
Selective treatment de-escalation in advanced prostate cancer: have we come full circle?
BJU Int
January 2025
Department of Urology, Singapore General Hospital, Singapore, Singapore.
Compelling evidence has solidified the notion of early treatment intensification in managing patients with metastatic hormone-sensitive prostate cancer (mHSPC). Landmark trials have provided Level 1 evidence for the survival benefits achieved by combining multiple agents. The efficacy of combined therapy relies not only on how treatment is intensified but also on how it is de-escalated.
View Article and Find Full Text PDFTotal penectomy as treatment option for solitary penile metastasis in hormone sensitive metastatic prostate cancer (mHSPC): Case report with surgical technique.
Urol Case Rep
January 2025
Department of Urology, Clinical Centre of Montenegro, Ljubljanska bb, 81000, Podgorica, Montenegro.
We present a case of a 66-year-old man with a three-year history of Gleason 10 prostate cancer (PCa), who presented with penile pain, erythema, and induration of the penile shaft. His cancer was treated with androgen deprivation therapy (ADT), radiotherapy, and apalutamide, resulting in PSA reduction; however, a solitary penile lesion persisted, necessitating radical penectomy. At 12 months post-surgery, PSA levels and magnetic resonance imaging findings remained stable, with no signs of metastasis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!